News

2019 - 2020

  • Categories:History
  • Author:
  • Origin:
  • Time of issue:2020-03-09
  • Views:0

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

2019 - 2020

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

  • Categories:History
  • Author:
  • Origin:
  • Time of issue:2020-03-09
  • Views:0

A heavy load and a long way to go

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO